CD8A and myeloid sarcoma: Furthermore, FTY reduced the activation level of CD8+CD20+ T cells compared to baseline (decrease in CD69, CXCR3, and CCR6 expression), but it appeared to increase the relative frequency of differentiated CD20+ T cells, showing higher proportions of TEM CD4+CD20+ and terminally differentiated CD3+CD20+ and lower proportions of naïve plus stem cell-like memory CD8+CD20+ and central memory (TCM) CD8+CD20+ cells compared to untreated MS [23].